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Abstract
Canine oral malignant melanoma is locally invasive and highly metastatic. At present, the
best option for local control is en bloc excision followed by radiation if excision margins
are incomplete. Adjuvantly, the role of chemotherapy is dubious while immunotherapy
appears encouraging. This retrospective study evaluated 155 dogs with oral malignant
melanomas (24 stage I, 54 stage II, 66 stage III and 11 stage IV) managed in a single insti-
tution. The aim was to evaluate the differences in median survival time (MST) and
disease-free interval (DFI) between dogs which, at presentation, were treated surgically
with a curative intent (group 1) vs those marginally excised only (group 2). MST in group
1 was longer than in group 2 (594 vs 458 days), but no significant difference was found
(P = .57); a statistical difference was, however, found for DFI (232 vs 183 days,
P = .008). In the subpopulation of vaccinated dogs, the impact of adjuvant anti-CSPG4
DNA electrovaccination was then evaluated (curative intent, group 3, vs marginal, group
4); a significant difference for both MST (1333 vs 470 days, respectively, P = .03) and
DFI (324 vs 184 days, respectively, P = .008) was found. Progressive disease was signifi-
cantly more common in dogs undergoing marginal excision than curative intent excision
for both the overall population (P = .03) and the vaccinated dogs (P = .02). This study
pointed out that, after staging, wide excision together with adjuvant immunotherapy
was an effective approach for canine oral malignant melanoma.
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1 | INTRODUCTION
Malignant melanoma is an aggressive tumour characterized by high
local invasiveness and metastatic potential in both humans and dogs.
The most frequent location in dogs is the oral cavity, accounting for
up to 30-40% of canine oral malignancies.1-3 The biological behaviour
of canine oral malignant melanoma (COMM) can be predicted based
on several clinical (site of growth, size and clinical stage)2-4 as well as
on histological and immunohistochemical factors (Ki67 expression,
mitotic index, degree of pigmentation and nuclear atypia).5,6 It has
also recently been shown that platelet-derived growth factor receptor
expression correlated with prognosis.7
It has been reported that COMM invades the bone in 57.0% of
cases.3,8 The metastatic rate is variable ranging from 30.3% to 74.0%
at the level of the regional lymph nodes,3,9 and from 14.0% to 92.0%
as distant metastatic spread (lungs and other organs).3
Factors such as the site of tumour growth (gum, internal lip/cheek,
palate, tongue and tonsil), the size and degree of local soft tissue, and
the bone invasion have a heavy impact on the choice of treatment for
local tumour control. For local tumour control with a curative intent, a
wide surgical excision should be performed. While evidence guiding
specific surgical margins is lacking, the authors aim for a minimum of
1.5-2 cm of macroscopically sound tissue all around the COMM, when
feasible. The reasons for an excision with no local curative intent may
include difficult tumour locations (including the tongue10 and the ton-
sil), first excision not performed by a surgeon specialized in veterinary
oncological surgery or justified as an excisional biopsy and, finally, mar-
ginal excision requested by the owner for palliation because of the
signs of foul odour and bleeding from a rapidly tumour growth. Radio-
therapy should be considered as adjuvant therapy for those COMMs
incompletely excised or, as a primary treatment or in combination with
medical treatment, for those cases deemed inoperable or when the
owners refuse surgery.11-18 An alternative to radiotherapy for local
tumour control is electrochemotherapy which would be con-
traindicated when tumour bone erosion is already evident.19-21
Distant metastasis from COMM, more than local recurrence, rep-
resents the definitive cause of death in the majority of dogs; there-
fore, there is the absolute need, once local control has been reached,
to adopt adjuvant systemic treatments in an attempt to delay the met-
astatic spread. Standard chemotherapy, based mainly on the use of
carboplatin, has failed to show real efficacy when used in an adjuvant
setting since survival did not appear to be prolonged significantly
when compared with local tumour control only.13-15,22-24 For all these
reasons, and also thanks to the immunogenic features of melanoma,
several studies dealing with immunotherapy have been carried out.
Melanoma-associated antigens have been identified (eg, Tyrosinase
and Chondroitin sulphate proteoglycan 4 [CSPG4]) and utilized in pro-
ducing vaccines capable of evoking an immune response against
COMM.25-32 In particular, the authors' attention was focused on
CSPG4, a cellular membrane antigen, characterized by restricted dis-
tribution in normal healthy tissues and high expression on neoplastic
cells in both human and canine MM. It coordinates several intracellu-
lar pathways regulating different cell functions (ie, proliferation,
migration and survival), thus being involved in tumourigenesis at mul-
tiple levels.33-36 In addition, CSPG4 has also been shown to be over-
expressed in melanoma cancer stem cells and associated with poorer
patient prognosis.29,37 All these features make CSPG4 an ideal antigen
to be safely and effectively targeted.
The aim of this retrospective study was to evaluate a) the differ-
ence in terms of prognosis (disease-free interval [DFI] and survival
time) between COMMs which, immediately after the first presenta-
tion, were treated surgically with a curative intent excision vs those
marginally excised only, b) the potential relationship between the type
of surgery performed and progressive disease, and c) the impact of
adjuvant anti-CSPG4 DNA electrovaccination on both survival and
DFI in the two groups of dogs.
2 | MATERIALS AND METHODS
2.1 | Patient enrolment
Client-owned dogs affected by COMMs which were presented at the
Veterinary Teaching Hospital of Grugliasco (Turin, Italy) of the Univer-
sity of Turin since January 1, 2000 with a minimum follow-up of 1 year
as of 30 September 2020 were retrospectively considered for this
study. The dogs were presented for surgical treatment, or for anti-
CSPG4 DNA electrovaccination or both after having already been oper-
ated elsewhere. Written consent was obtained from the owners for the
anaesthetic, diagnostic, histological, and surgical procedures before
staging. Regarding adjuvant anti-CSPG4 DNA electrovaccination, other
prospective studies have been carried out since 200927,28 and still
others are in progress. The dogs were treated according to the Good
Clinical Practice guidelines for animal clinical studies. Both the Ethics
Committee of the University of Turin and the Italian Ministry of Health
approved the trials (0004230-20/02/2018-DGSAF-MDS-P and
0015537-28/06/2017-DGSAF-MDS-P); specific written consent for
entry into the study was obtained from all the owners of the dogs
vaccinated.
2.2 | Tumour staging and treatment
Dogs were included if they had undergone a surgical excision of the
primary tumour with or without regional lymphadenectomy and if his-
tology confirmed a diagnosis of COMM. The data collected included
sex, age, weight and breed as well as tumour localisation and size, and
tumour-node-metastasis (TNM) classification based on Owen LN.38
For both the staging and the evaluation of the general health condi-
tion, all dogs underwent a complete clinical examination, a complete
blood examination (complete blood count and biochemistry) and a
more specific cardiological evaluation (echocardiography or electro-
cardiogram or both) when indicated; imaging included X-rays of the
thorax (three views) and abdominal ultrasound or total body com-
puted tomography (CT). Dogs were excluded from the study if distant
metastasis were detected before surgery. Dogs with concurrent
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diseases capable of negatively influencing a minimum follow-up of
1 year (mild to severe renal, hepatic or cardiac diseases or other
tumours) were also excluded. In addition, all the adjuvant treatments
adopted were recorded: metronomic therapy (piroxicam
+ cyclophosphamide + thalidomide), standard chemotherapy (cisplatin
or carboplatin), radiotherapy (hypofractionated protocol) and anti-
CSPG4 DNA electrovaccination.27-29
The surgical procedure used to resect COMM, excising only the
macroscopic tumour without any attempt to include any or just a few
millimetres of macroscopically normal surrounding tissue, was consid-
ered to be a marginal excision. If the excision was considered to have a
curative intent (for local tumour control only), an attempt was made to
include at least 1.5 cm up to 2 cm of macroscopically normal bone, soft
tissues or both (depending on the tumour location), independent of the
result of the histological evaluation of the inked excision margins (infil-
trated or non-infiltrated margins at histology). Moreover, the authors.
decided to consider as curative an en bloc resection performed immedi-
ately after a cytological evaluation or within 1 month from a previous
incisional or marginal excisional biopsy.
The histological data included the evaluation of the excision mar-
gins (not infiltrated, infiltrated or unknown), the mitotic index
(MI) (<4/10 high power fields [HPF] or ≥4/10 HPF) and Ki67 expres-
sion (<19.5% or ≥19.5%).5,6 All the excised regional lymph nodes were
sent to the histology laboratory for evaluation; if not excised, the
mandibular lymph nodes were aspirated and cytologically evaluated.
The entire population of dogs was divided and evaluated based
on the type of surgery performed (group 1, curative surgery; group
2, marginal excision). Subsequently, only vaccinated dogs were consid-
ered and were divided according to the type of surgery performed
(group 3, curative surgery plus electrovaccination; group 4, marginal
surgery plus electrovaccination). The DNA electrovaccination proce-
dure was performed only in dogs with COMMs which were character-
ized by a CSPG4 immunohistochemical expression ≥3/837 which was
selected as a cut-off value for inclusion in the immunization group.
Dogs, under brief general anaesthesia, were vaccinated with plasmids
coding for the CSPG4 antigen. The vaccination was started 1 to
3 weeks after surgery and was repeated after 2 weeks and then
monthly for a minimum of 6 and a maximum of 24 immunizations.
The CSPG4-coding plasmids (500 μg in 200 μL of 0.03% NaCl) were
injected into the muscles of the caudal thigh and, 2 minutes later, nine
electric pulses (1 high voltage, amplitude 450 V, length
50 milliseconds, frequency 3 HZ; 1 second pause; eight low-voltage
amplitude 110 V, length 20 milliseconds, pause 300 milliseconds)
were applied to the injection site using the CLINIPORATOR (Igea), an
instrument already approved for veterinary application. The dogs
were monitored for acute, late local or systemic side effects.27-29
2.3 | Patient monitoring
Vaccinated dogs received a monthly re-examination during which a
clinical examination, blood examinations and a total body CT scan were
performed. Dogs that were not vaccinated had re-examination every
3 months in the first year and every 6 months in the second year. At
each of these re-examinations, clinical examination, blood examina-
tions, chest radiographs and abdominal ultrasound were performed.
2.4 | Statistical analysis
The analyses were carried out using GraphPad Prism (version 9.0.0 for
Windows, GraphPad Software, San Diego, California, www.graphpad.
com), with statistical significance set at a P < .05. The data were sum-
marized using descriptive statistics, and were indicated as mean,
median and range. Distribution was checked graphically using the
Shapiro-Wilk Test; the Wilcoxon Rank Sum Test was then utilized to
evaluate the possible differences within the groups for age, weight,
Ki67 expression, MI and clinical tumour stage. The median DFI and sur-
vival time (MST) were evaluated using the Kaplan-Meier method; the
log-rank test was used to calculate the DFI and MST of the dogs in the
two treatment groups (curative intent—group 1—vs marginal excision—
group 2), and of the subpopulation of dogs which received the
anti-CSPG4 DNA vaccination and curative intent surgery (group 3) vs
vaccination and marginal surgery (group 4). The DFI was calculated from
the day of surgery to the first tumour recurrence or metastasis and ST
as the period from the day of surgery to the patient's death. Dogs which
died from non-COMM-related causes, those lost to follow-up and those
still alive at the end of the study were censored. Finally, the Fisher's
exact test was used to test a potential association between treatment
types and the probability of local recurrence and/or metastasis.
3 | RESULTS
3.1 | Demographics
One-hundred and fifty-five client-owned dogs were enrolled, of which
61 were female (46 spayed and 15 intact) and 94 were male (26 cas-
trated and 68 intact). The mean and the median ages at presentation
were 11.3 and 12.0 years, respectively (range 4-17 years); the mean
and the median weights were 22.0 and 21.0 Kg, respectively (range
2-55 kg; Table 1). Approximately one third of the dogs were mixed
breeds (53/155, 34.2%) while the remaining dogs (102/155, 65.8%)
belonged to 36 different pure breeds. In particular, there were Cocker
Spaniels (13 dogs), Golden Retrievers (12 dogs), German Shepherds
(8 dogs), 5 each of Dachshunds and Yorkshire Terriers, 4 each of Bea-
gles, Dwarf Schnauzers, Labrador Retrievers and Pinschers, 3 each of
Giant Schnauzers, Pekingese, Rottweilers and English Setters, with
the remaining dogs belonging to 23 different breeds.
3.2 | Tumour location, clinical staging and adjuvant
treatment
The COMM was localized at the level of the gum of the lower arcade
in 56 dogs (36.1%), the gum of the upper arcade in 36 dogs (23.2%),
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the mucosa of the cheek in 22 dogs (14.2%), the mucosa of the lip in
21 dogs (13.5%), the tongue in 10 dogs (6.5%), the palatine mucosa in
8 dogs (5.2%), and the tonsil in 2 dogs (1.3%) (Table 1).
Curative intent surgery consisted of 45 mandibulectomies,
27 maxillectomies and 37 cheek/lip en bloc excisions with or without
mucosal reconstruction or skin flap reconstructions or a combination
of both.
Mandibular lymphadenectomies were performed in 135 dogs, in
42 cases bilaterally (in three, the medial retropharyngeal lymph nodes
were also removed) while in 93 dogs only the ipsilateral mandibular
lymph nodes were removed. In 20 dogs, the lymph nodes were evalu-
ated using fine needle aspiration and cytological examination only.
The overall metastatic rate at the level of the regional lymph nodes
was 41.9% (65/155). In particular, 63/135 (46.7%) of the nodes surgi-
cally excised were histologically metastatic (20/42 [47.6%] bilaterally
removed and 43/93 [46.2%] ipsilaterally removed); of the 20 cases in
which only a cytological evaluation was performed, only 2 (10%) were
metastatic. This allowed establishing the definitive postoperative
tumour stage (parameter N of the TNM system).38
Clinical staging identified 24 stage I (15.5%), 54 stage II (34.8%),
66 stage III (42.6%) and 11 stage IV (7.1%) COMMs (bilateral metasta-
sis at the level of the regional lymph nodes only); stage IV COMMs
with distant metastasis were excluded (Table 1).
Data regarding adjuvant treatment are summarized in Table 2.
Eighty-two dogs underwent adjuvant DNA electrovaccination against
CSPG4, 10 dogs received adjuvant radiotherapy, 40 dogs had
metronomic treatment based on piroxicam, cyclophosphamide and
thalidomide, eight received standard chemotherapy (cisplatin in four
dogs and carboplatin in other four dogs) while electrochemotherapy
was used in five dogs (with bleomycin intravenous injection; Table 2).
3.3 | Histological evaluation and
immunohistochemical characterization of COMMs
Histology of the excision margins identified 68 (43.9%) COMMs with
non-infiltrated margins (67 curative intent and 1 marginal) and
43 (27.7%) COMMs with infiltrated margins (11 curative intent and
32 marginal); the excision margin status was unknown in 44 (28.4%)
COMMs (31 curative intent and 11 marginal; Table 3).
The mitotic index was ≥4/10 HPF in 102 COMMs, <4/10 HPF in
23 COMMs and was not available in 30 COMMs. The Ki67 expression
was ≥19.5% in 83 COMMs, <19.5% in 29 cases and not available in
43 COMMs (Table 3). Immunohistochemistry for CSPG4 was <3 in
40 COMMs (26%); the dogs bearing this COMM were only operated
and not vaccinated.
3.4 | Follow-up and statistical data
One-hundred and nine dogs (70.3%) experienced progressive disease,
of which 41 (37.6%) had a local recurrence only, 23 (21.1%) both a
TABLE 1 Clinical characteristics of the dogs enrolled in the study
Overall population (155) Curative intent surgery (109) Marginal surgery (46)
Age (Years) Mean 11.3 11.6 10.7
Median 12 12 11
Range 4-17 4-17 5-14.5
Weight (kg) Mean 22 21.3 23.7
Median 21 19 24
Range 2-55 2-52 3-55
Sex (%) Female intact 15 (9.7%) 9 (8.3%) 6 (13%)
Spayed 46 (29.7%) 31 (28.4%) 15 (32.6%)
Male intact 68 (43.8%) 49 (45%) 19 (41.4%)
Neutered 26 (16.8%) 20 (18.3%) 6 (13%)
Localisation (%) Mandible 56 (36.1%) 40 (36.7%) 16 (34.8%)
Maxilla 36 (23.2%) 26 (23.9%) 10 (21.8%)
Cheek 22 (14.2%) 19 (17.4%) 3 (6.5%)
Lip 21 (13.5%) 18 (16.5%) 3 (6.5%)
Tongue 10 (6.5%) 0 (0%) 10 (21.8%)
Palate 8 (5.2%) 6 (5.5%) 2 (4.3%)
Tonsil 2 (1.3%) 0 (0%) 2 (4.3%)
Clinical stage (%) Stage I 24 (15.5%) 19 (17.4%) 5 (10.9%)
Stage II 54 (34.8%) 32 (29.4%) 22 (47.8%)
Stage III 66 (42.6%) 50 (45.9%) 16 (34.8%)
Stage IV 11 (7.1%) 8 (7.3%) 3 (6.5%)
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local recurrence and distant metastasis, and 45 (41.3%) distant metas-
tases only (Table 4). At the end of the study, 14 (9.0%) dogs were still
alive (range 386-2632 days) while 135 (87.1%) had died, 85 (62.9%)
of which from COMM-related causes, and 6 (3.9%) were lost to
follow-up.
When the dogs were divided based on the type of surgery,
109 dogs had undergone a curative intent (group 1, 70.3%) and
46 dogs a marginal (group 2, 29.7%) excision. The MST in groups
1 and 2 was 594 (range 46-2632 days) and 458 days (range
149-1063 days), respectively; no statistical difference was found
(P = .57, Figure 1). The DFI in groups 1 and 2 was 232 (range
22-2632 days) and 183 days (range 13-1049 days), respectively; a
statistical difference was found (P = .008, Figure 2).
Since many dogs underwent adjuvant anti-CSPG4 DNA ele-
ctrovaccination, they were additionally subdivided with the aim of
verifying how much the immunological treatment had impacted the
outcomes. Eighty-two dogs (52.9%) underwent anti-CSPG4 DNA ele-
ctrovaccination, of which 51 had curative intent surgery (group
3, 62.2%) and 31 a marginal resection (group 4, 37.8%). The MST in
groups 3 and 4 was 1333 days (range 78-2632 days) and 470 days
(range 187-1063 days), respectively; a statistical difference was found
(P = .03, Figure 3). The DFI in Groups 3 and 4 was 324 (range
TABLE 2 Adjuvant therapy used in the dogs enrolled in the study
Overall population (155) Curative intent surgery (109) Marginal surgery (46)
Anti-CSPG4 electrovaccination 82 (52.9%) 51 (46.8%) 31 (67.4%)
Metronomic chemotherapy 40 (25.8%) 22 (20.2%) 18 (39.1%)
EV chemotherapy 8 (5.2%) 7 (6.4%) 1 (2.2%)
Radiation therapy 10 (6.5%) 5 (4.6%) 5 (10.9%)
Electrochemotherapy 5 (3.2%) 3 (2.7%) 2 (4.4%)
TABLE 3 Histological and immunohistochemical parameters of canine oral malignant melanoma present in the study
Overall population (155) Curative Intent Surgery (109) Marginal Surgery (46)
Margins Not infiltrated 68 (43.9%) 67 (61.5%) 1 (2.2%)
Infiltrated 43 (27.7%) 11 (10.1%) 32 (69.6%)
Unknown 44 (28.4%) 31 (28.4%) 13 (28.2%)
Mitotic index (MI) ≥4/10 HPF 102 (65.8%) 64 (58.7%) 38 (82.6%)
<4/10 HPF 23 (14.8%) 17 (15.6%) 6 (13.0%)
Unknown 30 (19.4%) 28 (25.7%) 2 (4.4%)
Ki67 ≥19,5 83 (53.6%) 54 (49.5%) 29 (63.0%)
<19,5 29 (18.7%) 16 (14.7%) 13 (28.3%)
Unknown 43 (27.7%) 39 (35.8%) 4 (8.7%)
TABLE 4 Follow-up of the dogs enrolled in the study
Local recurrence Distant metastasis (lung) Both metastasis and local recurrence
Overall population (155) Alive (14) 1 (7.1%) 3 (21.4%) 0 (0.0%)
COMM-related Death (85) 27 (31.8%) 36 (42.3%) 22 (25.9%)
Unrelated death (50) 11 (22.0%) 6 (12.0%) 1 (2.0%)
Lost to follow-up (6) 2 (33.3%) 0 (0.0%) 0 (0.0%)
Curative intent surgery (109) Alive (12) 1 (8.3%) 2 (16.7%) 0 (0.0%)
COMM-related death (57) 22 (38.6%) 25 (43.9%) 10 (17.5%)
Unrelated death (36) 7 (19.4%) 2 (5.6%) 1 (2.8%)
Lost to follow-up (4) 1 (25%) 0 (0.0%) 0 (0.0%)
Marginal surgery (46) Alive (2) 0 (0.0%) 1 (50.0%) 0 (0.0%)
COMM-related death (28) 5 (17.8%) 11 (39.3%) 12 (42.9%)
Unrelated death (14) 4 (28.6%) 4 (28.6%) 0 (0.0%)
Lost to follow-up (2) 1 (50.0%) 0 (0.0%) 0 (0.0%)
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37-2632 days) and 184 days (range 13-1049 days), respectively, with
a significant difference between the two groups (P = .008, Figure 4).
The survival and disease-free rates at 6, 12, 18 and 24-months
are reported in Table 5.
No association between the type of surgical excision performed
and the occurrence of local recurrence, either in the entire canine
population (P = .48) or in the dogs receiving the anti-CSPG4 DNA
electrovaccination (P = .49) was demonstrated. No association was
also found when the histology of the excision margins was compared
with the outcome (P = .18). Instead, a significant association was
found when the comparison was between the type of surgical exci-
sion (curative intent vs marginal) and progressive disease (local recur-
rence, metastasis only or recurrence plus distant metastasis) in both
the overall population (P = .03) and in vaccinated dogs (P = .02).
Finally, a significant association was found in the vaccinated dogs
between the status of the histological excision margins and local
recurrence (P = .04; Table 6).
4 | DISCUSSION
This retrospective study describes 155 dogs with COMMs treated
with surgery, of which 82 dogs also received adjuvant anti-CSPG4
DNA electrovaccination. Compared with the existing literature, no rel-
evant difference regarding age, breed, sex, weight and site of growth
of the COMM was found in this population of dogs or among the
groups.1-3,39
The dogs included in the study were first divided into two groups,
the first including dogs which had undergone curative intent surgery,
such as mandibulectomy, maxillectomy or lip/cheek en bloc resection,
followed, if required, by plastic reconstruction while the second group
included those dogs which had undergone a marginal excision only,
with no locally curative intent. Primary COMMs of the tongue and
tonsils were also included in the second group. The goal of this divi-
sion was to look for a potential statistical difference in outcome
between these two groups of dogs.
The evaluation of these two groups did not reveal any significant
difference in terms of Ki67 expression, MI and clinical stage, thus con-
firming a uniform distribution of the prognostic indicators reported.5,6
The MST in group 1 was longer than in group 2; however, no signifi-
cant difference was found (P = .57). Instead, significance was demon-
strated when the DFI of these two groups was evaluated (P = .008). It
should be noted that the MST recorded in both groups 1 and 2 was
superior to that reported in the study of Boston et al. (2014) in which
























F IGURE 1 Groups 1 and 2. Median survival time (MST) for
curative intent vs marginal surgery























F IGURE 2 Groups 1 and 2. Disease-free interval (DFI) for
curative intent vs marginal surgery
























F IGURE 3 Groups 3 and 4. Median survival time (MST) for
curative intent vs marginal surgery in vaccinated dogs























F IGURE 4 Groups 3 and 4. Disease-free interval (DFI) for
curative intent vs marginal surgery in vaccinated dogs
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a large proportion of dogs were only operated on (MST of 352 days),
and the use of different adjuvant therapies did not substantially
change the outcome (MST of 335 days)15; it was however lower when
compared with the results of the study of Tuohy et al. (2014) in which
the MST was 723 days.40 In the latter study, however, 74.3% of the
COMMs were stages I and II (51.4% and 22.9% respectively), and only
20% were stages III and IV (18.6% and 1.4% respectively) while, in the
present study, 50.3% of COMMs were stages I and II and 49.7% were
stages III and IV (Table 1). The elevated number of higher stages of
COMMs in the present population may explain this difference.40
An important variable in this study was that many of the dogs in
both group 1 and group 2 also underwent anti-CSPG4 DNA ele-
ctrovaccination, which had already demonstrated to be able to
increase both MST and DFI in COMMs.27-29 The authors' previous
and ongoing studies have demonstrated the high expression and prev-
alence of the CSPG4 antigen in COMMs.27-29,36,37 The CSPG4 anti-
gen has several interesting features ie high expression in the cell
membranes of neoplastic cells and low expression in the cells of
healthy tissues as well as playing a key role in multiple tumourigenic
processes.36 Authors believe that these features make this molecule
an ideal target in COMMs; DNA vaccination has been demonstrated
to be safe in companion animals and effective in inducing a specific
humoral and cellular response which could be long lasting.25,26,41,42
All these factors prompted the Authors to investigate the anti-CSPG4
DNA vaccination as an adjuvant option in treating COMM
patients.27,28 Both the latter studies and the ongoing clinical trials
have revealed the ability of anti-CSPG4 DNA electrovaccination to
induce a significant antibody response capable of binding the antigen
and likely inducing its down-modulation, impairing its tumourigenic
function.27-29 and unpublished data
The rate of CSPG4 expression at immunohistochemistry in this
series of dogs was not prognostic, as also already previously
reported.27 Additionally, when not vaccinated dogs were compared
based on the cut-off value of CSPG4, that is, < 3 vs ≥ 3, there was no
TABLE 5 Survival in months and DFI rate
Months
Overall population (155) Vaccinated dogs (82)
Curative intent surgery (109) Marginal surgery (46) Curative intent surgery (51) Marginal surgery (31)
Survival rate ≥6 78.9% 95.6% 94.1% 100%
≥12 51.1% 65.2% 72.5% 74.2%
≥18 39.8% 35.3% 54% 40%
≥24 28.1% 20% 35.5% 23.3%
DFI rate ≥6 65.1% 52.2% 72.5% 58%
≥12 37.6% 21.7% 43.1% 22.6%
≥18 25.9% 11.1% 30% 16.6%
≥24 22.3% 6.7% 24.4% 10%
TABLE 6 Fisher's Exact test
Curative intent surgery Marginal surgery P value Clear margins Infiltrated margins P value
Overall population (155)
Local recurrence 43 (39.4%) 21 (45.7%) .48 28 (41.2%) 21 (48.8%) .44
No recurrence 66 (60.6%) 25 (54.3%) 40 (58.8%) 22 (51.2%)
Total 109 46 68a 43a
Progressive disease 71 (65.1%) 38 (82.6%) .03 47 (69.1%) 35 (81.4%) .18
Stable disease 38 (34.9%) 8 (17.4%) 21 (30.9%) 8 (18.6%)
Total 109 46 68a 43a
Vaccinated dogs (82)
Local recurrence 23 (45.1%) 17 (54.8%) .49 20 (51.3%) 14 (82.4%) .04
No recurrence 28 (54.9%) 14 (45.2%) 19 (48.7%) 3 (17.6%)
Total 51 31 39a 17a
Progressive disease 32 (62.8%) 27 (87.1%) .02 27 (69.2%) 16 (94.1%) .08
Stable disease 19 (37.6%) 4 (12.9%) 12 (30.8%) 1 (2.9%)
Total 51 31 39a 17a
Note: Associations between type of surgery/histological margins and the probability of local recurrence and/or progressive disease. Bold values are for
those that are statistically significant
aUnknown margins were not considered.
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significant difference regarding the MST (280 days vs
320 days [P = .57]).
In order to avoid any potential confounding elements in evaluat-
ing the impact of the two different surgical approaches (curative
intent vs marginal) on the outcome, only vaccinated dogs receiving a
curative intent (group 3) or a marginal (group 4) surgical excision were
compared. Analysis showed a significant difference fin both MST
(P = .03) and DFI (P = .008), thus emphasizing the role of local surgical
control in dogs subsequently treated with anti-CSPG4 ele-
ctrovaccination in an attempt to also improve systemic control.
This study had some limitations. First of all, albeit this study dealt
with COMMs treated in a single institution, it was a retrospective study
which spanned a wide period of time during which imaging procedures
to detect systemic metastases progressively changed (from three view
X-rays of the thorax and abdominal ultrasound to total body CT scan),
the latter being the most used in recent years); even the procedures for
histological evaluation of the excision margins have been progressively
improved. It should be noted that the histological evaluation of the
excision margins was not available in 44/155 (28.4%) cases.
The second issue was relative to the evaluation of the regional
lymph node status. In the past, this evaluation was based on cytology
only or on its/their removal only when enlarged; recently it has been
shown that this method does not reliably determine the N parameter
of the TNM staging system.9,43 Currently, lymph node staging is based
on their surgical removal and histologic examination, regardless of size
and shape; in addition, more accurate imaging techniques, addressed
to identifying either the regional or, more specifically, the sentinel
lymph nodes, have been implemented.44-50 According to this, some of
the dogs in the present study had undergone cytology only (older
cases), others ipsilateral mandibular lymph node excision, others ipsi-
lateral mandibular and medial retropharyngeal lymph node excision,
and, more lately, bilateral and medial retropharyngeal lymph node
excision. At present, the latter is the procedure which the authors rou-
tinely perform for COMM. Finally, the results of the cytological vs his-
tological evaluation of the regional lymph nodes reported herein
would indicate that histology appears to be more accurate than cytol-
ogy in establishing the lymph node status (10% of the lymph nodes
examined cytologically vs over 40% in those examined histologically).
The above limitations may have underestimated the tumour clini-
cal stage, especially of the older cases but, on the other hand, this
should be considered favourably when compared with the most
recent retrospective studies.15,40
An important difference between the vaccinated (vaccination is
still a clinical trial approved by the Italian Ministry of Health) and not
vaccinated dogs is the closer monitoring of the former. As a conse-
quence, local recurrences, systemic metastasis or both may have been
diagnosed later in not vaccinated dogs compared with vaccinated
dogs. Therefore, the DFI in not vaccinated dogs may have been over-
estimated. However, this unequal follow-up does not influence the
overall survival data.
At present, the authors do not have any specific data to present
regarding metronomic therapy. They strongly believe that this would
require a clinical trial addressed only to the evaluation of its efficacy.
This variable was very difficult to monitor; however, it may be said
from an empirical point of view that this treatment was capable, likely
together with electrovaccination, of stabilizing the disease in many
cases, apparently avoiding the rapid progression of metastasis of
COMM. However, additional studies on this treatment are warranted.
It can be concluded that a curative intent surgical approach, when
feasible, is advisable in an attempt to prolong both the DFI and survival.
The positive association between the type of surgery and the outcome
confirmed this aspect; an association was also found when the histolog-
ical status of the excision margins was considered in the vaccinated
dogs; however, this was not the case in the overall population. The lat-
ter result should be considered cautiously as the histological evaluation
of the excision margins was not available in all cases. Finally, it can also
be concluded that adjuvant anti-CSPG4 DNA electrovaccination may
additionally improve the outcome. Therefore, in the authors' experience
a curative intent surgical procedure plus an adjuvant anti-CSPG4 DNA
electrovaccination represented a valid therapeutic approach for COMM
when considering MST, DFI, survival time and DFI rates.
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